Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 78223, held by Actavis Mid Atlantic. Clobetasol Propionate.
As of Nov 16, 2026, ANDA 78223 (Clobetasol Propionate), held by Actavis Mid Atlantic, was first approved by FDA on Dec 4, 2008, with 1 approved supplement and 0 published complete response letters.
Clobetasol Propionate Lotion, 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, in patients 18 years of age or older.. Limitations of Use: Do not use on the face, axillae or groin. Do not use if atrophy is present at the treatment site. Do not use for rosacea or perioral dermatitis. 1.1 Indication
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2008 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clobetasol Propionate0.05% · lotion;topical | Clobetasol Propionate | Rx |
| Jun 29, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 4, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters